Xilio Therapeutics
32 hedge funds and large institutions have $52.2M invested in Xilio Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 15 closing their positions.
3.26% less ownership
Funds ownership: 68.35% → 65.1% (-3.3%)
22% less funds holding
Funds holding: 41 → 32 (-9)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
61% less capital invested
Capital invested by funds: $133M → $52.2M (-$80.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$649K |
| 2 |
LCM
Laurion Capital Management
New York
|
+$540K |
| 3 |
Renaissance Technologies
New York
|
+$285K |
| 4 |
Millennium Management
New York
|
+$189K |
| 5 |
B
Bailard
Foster City,
California
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.33M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.15M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.05M |
| 4 |
BlackRock
New York
|
-$952K |
| 5 |
State Street
Boston,
Massachusetts
|
-$295K |
XLO Hedge Fund Activity: Q2 2022 in Review
32 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2022, worth a combined $52.2M — down 61% from $133M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of XLO and 7 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 5 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $649K. The largest seller was RA Capital Management, cutting an estimated $1.33M.
- 32 institutional investors held Xilio Therapeutics (XLO) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $52.2M of Xilio Therapeutics stock for Q2 2022, down 61% quarter-over-quarter.
- 7 funds opened new Xilio Therapeutics positions in Q2 2022 and 15 closed out, a net change of -8 holders.
- The largest Xilio Therapeutics buyer in Q2 2022 was Rock Springs Capital Management, an estimated $649K added.
- The largest Xilio Therapeutics seller in Q2 2022 was RA Capital Management, an estimated $1.33M sold.
Based on aggregated 13F filings for Q2 2022.